INCY SEC Filing News — Incyte Corporation

Latest SEC filings for Incyte Corporation (INCY) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-…
Sector: Healthcare Industry: Biotechnology Market Cap: $23.1B
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
13
Insider Transactions
1
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for INCY currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
INCY Filing Activity Snapshot 2026-08-04 — 2026-10-15
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$5.73M
Mayes Patrick A (EVP & Chief Scientific Officer) · 2026-08-04
47,954 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Incyte Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 7 open-market sale, 3 compensation award and 3 tax withholding. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×3
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Tax withholding ×3
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Form 4 Tax withholding Tax / Compensation Filing 2026-10-05

INCY insider Form 4 filed for equity award, exercise, or tax withholding

Heeson Lee (EVP, Head of Incyte Intl) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 463 $117.14 $54.2K
Filing: Form 4 (Insider Transaction) Insider: Heeson Lee (EVP, Head of Incyte Intl) Shares: 463
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

INCY insider Form 4 filed for equity award, exercise, or tax withholding

BAKER BROS. ADVISORS LP (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 322 — —
A Compensation award 322 — —
Filing: Form 4 (Insider Transaction) Insider: BAKER BROS. ADVISORS LP (Director, 10% Owner) Shares: 644
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

INCY insider Form 4 filed for equity award, exercise, or tax withholding

Clancy Paul J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 203 $121.35 $24.6K
Filing: Form 4 (Insider Transaction) Insider: Clancy Paul J (Director) Shares: 203
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

INCY insider Form 4 filed for equity award, exercise, or tax withholding

HARRIGAN EDMUND (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 206 $121.35 $25.0K
Filing: Form 4 (Insider Transaction) Insider: HARRIGAN EDMUND (Director) Shares: 206
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-09-24

INCY insider Form 4 filed for equity award, exercise, or tax withholding

Gardner David H (EVP, Chief Strategy Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 920 $126.93 $116.8K
Filing: Form 4 (Insider Transaction) Insider: Gardner David H (EVP, Chief Strategy Officer) Shares: 920
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-17

INCY insider CAGNONI PABLO J (President, Global Head of R&D) sold 23,218 shares (~$2.80M)

CAGNONI PABLO J, listed as President, Global Head of R&D at INCYTE CORP, reported an open-market sale of 23,218 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,957 $61.76 $182.6K
M Option exercise 4,551 $61.18 $278.4K
M Option exercise 6,477 $64.25 $416.1K
M Option exercise 9,233 $71.93 $664.1K
S Open-market sale 9,233 $120.50 $1.11M
S Open-market sale 13,985 $120.49 $1.69M
M Option exercise derivative · Employee Stock Option (right to buy) 2,957 — —
M Option exercise derivative · Employee Stock Option (right to buy) 4,551 — —
M Option exercise derivative · Employee Stock Option (right to buy) 6,477 — —
M Option exercise derivative · Employee Stock Option (right to buy) 9,233 — —
Filing: Form 4 (Insider Transaction) Insider: CAGNONI PABLO J (President, Global Head of R&D) Shares: 23,218 Est. Value: $2.80M
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-08-27

INCY insider Form 4 filed for equity award, exercise, or tax withholding

Basi Ramitpal K (EVP, Human Resources) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 504 $129.72 $65.4K
Filing: Form 4 (Insider Transaction) Insider: Basi Ramitpal K (EVP, Human Resources) Shares: 504
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

INCY insider CAGNONI PABLO J (President, Global Head of R&D) sold 10,801 shares (~$1.36M)

CAGNONI PABLO J, listed as President, Global Head of R&D at INCYTE CORP, reported an open-market sale of 10,801 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,801 $125.56 $1.36M
Filing: Form 4 (Insider Transaction) Insider: CAGNONI PABLO J (President, Global Head of R&D) Shares: 10,801 Est. Value: $1.36M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-14

INCY insider CAGNONI PABLO J (President, Global Head of R&D) sold 10,803 shares (~$1.30M)

CAGNONI PABLO J, listed as President, Global Head of R&D at INCYTE CORP, reported an open-market sale of 10,803 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,803 $120.04 $1.30M
Filing: Form 4 (Insider Transaction) Insider: CAGNONI PABLO J (President, Global Head of R&D) Shares: 10,803 Est. Value: $1.30M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

INCY insider CAGNONI PABLO J (President, Global Head of R&D) sold 10,640 shares (~$1.31M)

CAGNONI PABLO J, listed as President, Global Head of R&D at INCYTE CORP, reported an open-market sale of 10,640 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,640 $122.69 $1.31M
Filing: Form 4 (Insider Transaction) Insider: CAGNONI PABLO J (President, Global Head of R&D) Shares: 10,640 Est. Value: $1.31M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

INCY insider Mayes Patrick A (EVP & Chief Scientific Officer) sold 2,207 shares (~$273.6K)

Mayes Patrick A, listed as EVP & Chief Scientific Officer at INCYTE CORP, reported an open-market sale of 2,207 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,207 $106.47 $235.0K
S Open-market sale 2,207 $123.99 $273.6K
M Option exercise derivative · Employee Stock Option (right to buy) 2,207 — —
Filing: Form 4 (Insider Transaction) Insider: Mayes Patrick A (EVP & Chief Scientific Officer) Shares: 2,207 Est. Value: $273.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-04

INCY insider CAGNONI PABLO J (President, Global Head of R&D) sold 15,888 shares (~$1.90M)

CAGNONI PABLO J, listed as President, Global Head of R&D at INCYTE CORP, reported an open-market sale of 15,888 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 15,888 $119.70 $1.90M
Filing: Form 4 (Insider Transaction) Insider: CAGNONI PABLO J (President, Global Head of R&D) Shares: 15,888 Est. Value: $1.90M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-04

INCY insider Mayes Patrick A (EVP & Chief Scientific Officer) sold 47,954 shares (~$5.73M)

Mayes Patrick A, listed as EVP & Chief Scientific Officer at INCYTE CORP, reported an open-market sale of 47,954 INCY shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 2,918 $61.18 $178.5K
M Option exercise 2,284 $64.25 $146.7K
M Option exercise 2,709 $61.76 $167.3K
M Option exercise 3,148 $68.62 $216.0K
M Option exercise 2,072 $71.93 $149.0K
M Option exercise 9,459 $72.27 $683.6K
M Option exercise 2,623 $74.78 $196.1K
M Option exercise 2,864 $77.67 $222.4K
M Option exercise 1,643 $80.50 $132.3K
M Option exercise 3,023 $83.20 $251.5K
M Option exercise 2,623 $83.58 $219.2K
M Option exercise 1,642 $85.01 $139.6K
M Option exercise 2,293 $90.56 $207.7K
M Option exercise 85 $106.47 $9.0K
M Option exercise 326 $105.43 $34.4K
S Open-market sale 14,661 $119.46 $1.75M
S Open-market sale 5,332 $119.42 $636.7K
S Open-market sale 2,187 $119.47 $261.3K
S Open-market sale 6,171 $119.43 $737.0K
S Open-market sale 4,695 $119.39 $560.5K
S Open-market sale 2,864 $119.40 $342.0K
S Open-market sale 1,643 $119.51 $196.4K
S Open-market sale 1,642 $119.38 $196.0K
S Open-market sale 85 $122.19 $10.4K
S Open-market sale 326 $121.69 $39.7K
S Open-market sale 2,293 $119.41 $273.8K
M Option exercise 6,055 $105.43 $638.4K
S Open-market sale 6,055 $120.43 $729.2K
M Option exercise derivative · Employee Stock Option (right to buy) 2,918 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,284 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,709 — —
M Option exercise derivative · Employee Stock Option (right to buy) 3,148 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,072 — —
M Option exercise derivative · Employee Stock Option (right to buy) 9,459 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,623 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,864 — —
M Option exercise derivative · Employee Stock Option (right to buy) 1,643 — —
M Option exercise derivative · Employee Stock Option (right to buy) 3,023 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,623 — —
M Option exercise derivative · Employee Stock Option (right to buy) 1,642 — —
M Option exercise derivative · Employee Stock Option (right to buy) 2,293 — —
M Option exercise derivative · Employee Stock Option (right to buy) 85 — —
M Option exercise derivative · Employee Stock Option (right to buy) 326 — —
M Option exercise derivative · Employee Stock Option (right to buy) 6,055 — —
Filing: Form 4 (Insider Transaction) Insider: Mayes Patrick A (EVP & Chief Scientific Officer) Shares: 47,954 Est. Value: $5.73M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Incyte Corporation has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-15

INCY Form 144 filed for proposed insider sale by PABLO CAGNONI (2,642 shares) ~$297.8K

PABLO CAGNONI filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PABLO CAGNONI Shares: 2,642 Est. Value: $297.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-15

INCY Form 144 filed for proposed insider sale by PABLO CAGNONI (23,218 shares) ~$2.80M

PABLO CAGNONI filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PABLO CAGNONI Shares: 23,218 Est. Value: $2.80M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-19

INCY Form 144 filed for proposed insider sale by PABLO CAGNONI (10,801 shares) ~$1.36M

PABLO CAGNONI filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PABLO CAGNONI Shares: 10,801 Est. Value: $1.36M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-12

INCY Form 144 filed for proposed insider sale by PABLO CAGNONI (10,803 shares) ~$1.30M

PABLO CAGNONI filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PABLO CAGNONI Shares: 10,803 Est. Value: $1.30M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-05

INCY Form 144 filed for proposed insider sale by PABLO CAGNONI (10,640 shares) ~$1.31M

PABLO CAGNONI filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PABLO CAGNONI Shares: 10,640 Est. Value: $1.31M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-05

INCY Form 144 filed for proposed insider sale by PATRICK A MAYES (2,207 shares) ~$273.6K

PATRICK A MAYES filed a Form 144 with the SEC indicating intent to sell INCY (INCYTE CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PATRICK A MAYES Shares: 2,207 Est. Value: $273.6K
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Incyte Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-31

INCY filed 8-K — material company event

INCYTE CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →

How we classify Incyte Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on INCY. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — INCY SEC Filings

More Tools for INCY

INCY Full Stock Analysis INCY Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper INCY analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the INCY stock analysis page.

INCY Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer